MCAM and rhabdoid tumor: More importantly, CD146+ cells were present in primary malignant rhabdoid tumors and exhibited exclusive in vivo tumorigenic potential sufficiently to suggest its utility as a potent biomarker for risk stratification and possibly treatment of malignant rhabdoid tumors.